Abstract: The disclosure relates to interferon lambda fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and/or dimers, vectors and transformed cells including such nucleic acid molecules, pharmaceutical compositions including the interferon lambda fusion polypeptides and/or dimers, and methods of treating a disorder in a human subject by administering the polypeptides and/or dimers.

Abstract: We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess.

Abstract: We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said proteins.

Abstract: We describe a circularly permuted growth hormone polypeptide antagonist; compositions comprising said antagonist and methods to treat conditions that would benefit from administration of said antagonist.

Abstract: The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Abstract: We describe a chimeric protein comprising a growth hormone polypeptide linked to a polypeptide comprising the extracellular binding domain of growth hormone receptor; its use in enhancing the growth and metabolism of non-human animals and homodimers comprising said chimeric protein.

Abstract: Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains.

Abstract: We disclose therapeutic polypeptides comprising at least two domains capable of binding to a cytokine receptor, wherein the domains are connected by a peptide linker, wherein the linker optionally comprises a rigid alpha helical region.

Abstract: The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of said modified growth hormone binding domains.

Abstract: Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents.

Abstract: This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.

Abstract: We describe modified cytokine ligand polypeptides comprising a modified amino acid sequence which is a modification of the native cytokine amino acid sequence of said ligand, wherein the native amino terminal and carboxyl terminal amino acid residues of the native polypeptide are linked, directly or indirectly, together, characterised in that said ligand is provided with alternative amino terminal and carboxyl terminal amino acid residues and further wherein at least one binding domain for said ligand's cognate binding partner or receptor complex is disrupted.

Abstract: The invention relates to the provision of oligomeric polypeptides (dimers, trimers etc) comprising the ligand binding domains of cytokines which are linked via flexible polypeptide linker molecules. The linker molecules optionally comprise protease sensitive sites to modulate the release of biologically active cytokines when administered to a human or animal subject.

Abstract: The invention relates to chimeric recombinant polypeptides, preferably therapeutic polypeptides, for example cytokines or antibodies, which are engineered to include a signal sequence for the attachment of glycosylphosphatidylinositol; cells expressing said polypeptides and methods to manufacture said polypeptides.

Abstract: The invention relates to the provision of oligomeric polypeptides (dimers, trimmers, etc) comprising the ligand binding domains of cytokines which are linked via flexible polypeptides linker molecules. The linker molecules optionally comprise protease sensitive sites to modulate the release of biologically active cytokines when administered to a human or animal subject.

Abstract: The invention relates to chimeric polypeptides wherein said polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of said modified growth hormone binding domains.

Abstract: This invention relates to agents which bind to cell surface receptors; methods to manufacture said agents; therapeutic compositions comprising said agents; and screening methods to identify novel agents.